ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
사르코이드증 시장 규모는 향후 몇 년 동안 15.6%의 연평균 성장률(CAGR)로 2029년까지 614억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 새로운 생물학적 치료법에 대한 수요 증가, 맞춤형 의료 접근법 채택 확대, 사르코이드증 유전자 치료에 대한 투자 증가, 표적 면역치료제 개발에 대한 관심 증가, 난치성 사르코이드증에 대한 치료제 파이프라인 확대 등 여러 요인에 의해 주도될 것으로 예상됩니다. 견인할 것으로 예상됩니다. 예측 기간 동안 예상되는 주요 동향으로는 생물학적 치료의 발전, 나노기술 기반 약물전달 시스템의 발전, 재생의학 및 줄기세포 치료의 발전, 3D 이미징 및 방사선의학 혁신, 임상 데이터 관리에 블록체인 기술의 통합 등이 있습니다.
개인맞춤의료의 중요성이 부각되면서 사르코이드증 시장의 향후 성장이 기대되고 있습니다. 맞춤의료는 유전적 체질, 바이오마커, 환경적 요인, 라이프스타일에 따라 환자 개개인에 맞게 치료 전략을 조정하여 보다 정확하고 효과적이며 표적화된 개입을 보장하는 첨단 의료 접근법입니다. 개인의 생물학적 프로파일에 따라 치료를 맞춤화함으로써 치료 효과를 높이고 부작용을 최소화할 수 있기 때문에 맞춤형 의료에 대한 수요가 증가하고 있습니다. 사르코이드증의 경우, 맞춤의료는 유전자, 바이오마커, 임상 프로파일링에 따라 치료를 조정하여 효능을 높이고 부작용을 줄입니다. 이 방법은 표적 치료를 강화하고, 질병의 불균일성을 해결하며, 개별 환자의 요구를 충족시킬 수 있습니다. 예를 들어, 2024년 2월 미국 비영리단체인 개인화된 의학 연합(Personalized Medicine Coalition)은 미국 식품의약국(FDA)이 2023년 희귀질환에 대한 16개의 새로운 개인화된 치료법을 승인했다고 보고했습니다. 그 결과, 맞춤의료에 대한 관심이 높아지면서 사르코이드증 시장의 성장을 견인하고 있습니다.
사르코이드증 시장에서 사업을 전개하고 있는 주요 기업들은 항TNFa 단클론항체 치료제와 같은 최첨단 치료법을 개발하여 염증성 질환 치료의 미충족 의료 수요에 대응하는 새로운 생물학적 솔루션을 제공하고 있습니다. 항종양괴사인자 알파(항TNFa) 단클론항체 치료제는 단클론항체를 이용해 염증성 사이토카인인 TNFa를 차단함으로써 염증을 억제하고 자가면역질환을 관리하는 표적 면역치료제입니다. 예를 들어, 미국에 본사를 둔 임상 단계의 바이오 치료제 기업 Xentria, Inc.는 2023년 11월, 자사의 주요 후보물질인 XTMAB-16이 유럽의약품청(EMA)으로부터 희귀질환 치료제로 지정되는 중요한 이정표를 달성했습니다. 또한, 폐 사르코이드증에 대한 세계 임상시험을 시작했으며, 첫 환자를 등록했으며, TNFa를 표적으로 하는 단클론항체인 XTMAB-16이 폐 사르코이드증의 염증 경로를 조절하고 부신피질 스테로이드 기반 치료제의 대체 표적을 제공할 수 있는 가능성을 연구하고 있습니다. 연구되고 있습니다. 이러한 규제 당국의 승인과 임상 진행은 희귀질환에 대한 혁신적인 생물학적 제제에 대한 전세계의 관심이 높아지고 있으며, 혁신적인 치료제로 미충족 의료 수요를 충족시키려는 젠트리아의 노력을 강조하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 사르코이드증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 사르코이드증 시장 : 성장률 분석
세계의 사르코이드증 시장 실적 : 규모와 성장, 2019-2024년
세계의 사르코이드증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 사르코이드증 전체 시장(TAM)
제6장 시장 세분화
세계의 사르코이드증 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
폐 사르코이드증
안구 사르코이드증
신경 사르코이드증
심장 사르코이드증
근골격계 사르코이드증
피부 사르코이드증
신장 사르코이드증
간 사르코이드증
비장과 골수 사르코이드증
세계의 사르코이드증 시장 : 진단 방법별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
영상 기술
생검
혈액 검사
세계의 사르코이드증 시장 : 치료 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
코르티코스테로이드
면역억제제
생물학적 제제
항말라리아제
세계의 사르코이드증 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
비경구
기타 투여 경로
세계의 사르코이드증 시장 : 최종 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 사르코이드증 시장, 피부 사르코이드증 병형별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
낭창성 낭창
결절성홍반
구진 사르코이드증
플라크 사르코이드증
피하 사르코이드증
세계의 사르코이드증 시장, 신장 사르코이드증 병형별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
육아종성 간질성 신장염
신장 석회 화 증
고칼슘뇨증 유발성 신장질환
세계의 사르코이드증 시장, 간 사르코이드증 병형별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
육아종성 간염
문맥압항진증
간섬유증
세계의 사르코이드증 시장, 비장과 골수 사르코이드증 하위 세분화(유형별), 실적과 예측, 2019-2024년, 2024-2029년, 2034년
비종
범혈구 감소증
골수 육아종
제7장 지역별·국가별 분석
세계의 사르코이드증 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 사르코이드증 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
사르코이드증 시장 : 경쟁 구도
사르코이드증 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb Company
Fresenius Kabi USA LLC
AstraZeneca plc
GlaxoSmithKline plc(GSK)
Eli Lilly and Company
Boehringer Ingelheim GmbH
Regeneron Pharmaceuticals Inc.
UCB Pharma
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.
Lupin Limited
Mallinckrodt Pharmaceuticals
Xentria Inc.
Molecure SA
Relief Therapeutics Holding AG
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
사르코이드증 시장 2029년 : 새로운 기회를 제공하는 국가
사르코이드증 시장 2029년 : 새로운 기회를 제공하는 부문
사르코이드증 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Sarcoidosis is a complex inflammatory condition marked by the formation of granulomas small clusters of immune cells that can develop in various organs, most commonly the lungs and lymph nodes. This can lead to organ dysfunction, respiratory problems, or other systemic issues. While the exact cause remains unknown, it is thought to involve an abnormal immune response triggered by environmental or genetic factors.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
There are several types of sarcoidosis, including pulmonary, ocular, neurosarcoidosis, cardiac, musculoskeletal, cutaneous, renal, hepatic, and sarcoidosis affecting the spleen and bone marrow. Pulmonary sarcoidosis, specifically, is a chronic inflammation of the lungs characterized by granuloma formation, which may result in symptoms such as cough, shortness of breath, and lung fibrosis if not managed properly. Diagnosing these conditions involves various methods, such as imaging techniques, biopsies, and blood tests. Treatment options include corticosteroids, immunosuppressive medications, biologics, and anti-malarial drugs, which can be administered through different routes such as oral or parenteral. These treatments are commonly used in hospitals, clinics, surgical centers, and diagnostic facilities.
The sarcoidosis market research report is one of a series of new reports from The Business Research Company that provides sarcoidosis market statistics, including sarcoidosis industry global market size, regional shares, competitors with a sarcoidosis market share, detailed sarcoidosis market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis industry. This sarcoidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcoidosis market size has grown rapidly in recent years. It will grow from$29.75 billion in 2024 to $34.46 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth observed in the historic period can be attributed to several factors, including heightened awareness of sarcoidosis among healthcare professionals, an increase in the prevalence of the disease in developed countries, the widespread use of corticosteroid-based treatments as the primary therapy, greater research funding for rare diseases, and a growing number of clinical trials focused on sarcoidosis treatments.
The sarcoidosis market size is expected to see rapid growth in the next few years. It will grow to$61.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth during the forecast period is expected to be driven by several factors, including a rising demand for novel biologic therapies, greater adoption of personalized medicine approaches, increased investments in gene therapy for sarcoidosis, a growing focus on targeted immunotherapy developments, and the expansion of drug pipelines for treating refractory sarcoidosis cases. Key trends anticipated in the forecast period include advancements in biologic therapies, progress in nanotechnology-based drug delivery systems, developments in regenerative medicine and stem cell therapy, innovations in 3D imaging and radiomics, and the integration of blockchain technology in clinical data management.
The growing emphasis on personalized medicine is expected to drive the growth of the sarcoidosis market in the future. Personalized medicine is an advanced medical approach that tailors treatment strategies to individual patients based on their genetic makeup, biomarkers, environmental factors, and lifestyle, ensuring more precise, effective, and targeted interventions. The demand for personalized medicine is increasing as it allows for treatments that are customized to an individual's biological profile, enhancing effectiveness and minimizing side effects. In the case of sarcoidosis, personalized medicine tailors treatment based on genetic, biomarker, and clinical profiling to improve efficacy and reduce adverse effects. This method enhances targeted therapy, addressing the disease's heterogeneity and responding to individual patient needs. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, up from just 6 treatments in 2022. As a result, the increasing focus on personalized medicine is boosting the growth of the sarcoidosis market.
Key companies operating in the sarcoidosis market are working on developing cutting-edge treatments, such as anti-TNFa monoclonal antibody therapy, to provide a novel biologic solution to address unmet medical needs in treating inflammatory diseases. Anti-tumor necrosis factor-alpha (anti-TNFa) monoclonal antibody therapy is a targeted immunotherapy that uses monoclonal antibodies to block TNFa, a pro-inflammatory cytokine, thereby reducing inflammation and managing autoimmune diseases. For instance, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, achieved a significant milestone when its lead candidate, XTMAB-16, received Orphan Drug Designation from the European Medicines Agency (EMA). The company also launched a global clinical study for pulmonary sarcoidosis, enrolling the first patient. XTMAB-16, a monoclonal antibody targeting TNFa, is being studied for its potential to regulate inflammatory pathways in pulmonary sarcoidosis, providing a targeted alternative to corticosteroid-based therapies. This regulatory recognition and clinical progress highlight the growing global interest in innovative biologics for rare diseases, emphasizing Xentria's commitment to meeting unmet medical needs with transformative treatments.
In June 2023, Xentria Inc., a US-based biotherapeutics company, entered into a partnership with Meitheal Pharmaceuticals Inc. to speed up the development and commercialization of XTMAB-16. Under this collaboration, Meitheal Pharmaceuticals obtained exclusive commercialization rights for XTMAB-16 in North America, while Xentria continued to lead the clinical development and regulatory progress. This partnership aims to increase market access and improve treatment options for patients with pulmonary sarcoidosis by leveraging Xentria's expertise in biologics and Meitheal's strong commercialization capabilities. Meitheal Pharmaceuticals, Inc. is a US-based biopharmaceutical company that specializes in developing and commercializing generic injectables, fertility treatments, biologics, and branded products.
Major players in the sarcoidosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi USA LLC, AstraZeneca plc, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., UCB Pharma, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc., Molecure SA, and Relief Therapeutics Holding AG.
Europe was the largest region in the sarcoidosis market in 2024. The regions covered in sarcoidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sarcoidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sarcoidosis market includes revenues earned by entities by providing services such as diagnostic tests, laboratory testing, gene therapies, disease management services, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcoidosis market also includes sales of corticosteroids, immunosuppressive agents, and antimalarial drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sarcoidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sarcoidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for sarcoidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoidosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Pulmonary Sarcoidosis; Ocular Sarcoidosis; Neurosarcoidosis; Cardiac Sarcoidosis; Musculoskeletal Sarcoidosis; Cutaneous Sarcoidosis; Renal Sarcoidosis; Hepatic Sarcoidosis; Sarcoidosis Of The Spleen And Bone Marrow
2) By Diagnostic Method: Imaging Technique; Biopsy; Blood Tests
3) By Treatment Type: Corticosteroids; Immunosuppressive Agents; Biologics; Anti-Malarial Drugs
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End Uses: Hospitals And Clinics; Surgical Centers; Diagnostic Centers; Other End Uses
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Sarcoidosis Market Characteristics
3. Sarcoidosis Market Trends And Strategies
4. Sarcoidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Sarcoidosis Growth Analysis And Strategic Analysis Framework
5.1. Global Sarcoidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Sarcoidosis Market Growth Rate Analysis
5.4. Global Sarcoidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Sarcoidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Sarcoidosis Total Addressable Market (TAM)
6. Sarcoidosis Market Segmentation
6.1. Global Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pulmonary Sarcoidosis
Ocular Sarcoidosis
Neurosarcoidosis
Cardiac Sarcoidosis
Musculoskeletal Sarcoidosis
Cutaneous Sarcoidosis
Renal Sarcoidosis
Hepatic Sarcoidosis
Sarcoidosis Of The Spleen And Bone Marrow
6.2. Global Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Technique
Biopsy
Blood Tests
6.3. Global Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Immunosuppressive Agents
Biologics
Anti-Malarial Drugs
6.4. Global Sarcoidosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Route Of Administrations
6.5. Global Sarcoidosis Market, Segmentation By End Uses, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Surgical Centers
Diagnostic Centers
Other End Uses
6.6. Global Sarcoidosis Market, Sub-Segmentation Of Pulmonary Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Pulmonary Sarcoidosis
Chronic Pulmonary Sarcoidosis
Fibrotic Pulmonary Sarcoidosis
6.7. Global Sarcoidosis Market, Sub-Segmentation Of Ocular Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis
Optic Neuropathy
6.8. Global Sarcoidosis Market, Sub-Segmentation Of Neurosarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Meningeal Neurosarcoidosis
Cranial Nerve Neurosarcoidosis
Peripheral Neuropathy
Spinal Cord Involvement
Hypothalamic-Pituitary Involvement
6.9. Global Sarcoidosis Market, Sub-Segmentation Of Cardiac Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atrioventricular Block
Ventricular Arrhythmias
Heart Failure
Myocarditis
Sudden Cardiac Arrest
6.10. Global Sarcoidosis Market, Sub-Segmentation Of Musculoskeletal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Arthritis
Myopathy
Bone Lesions
6.11. Global Sarcoidosis Market, Sub-Segmentation Of Cutaneous Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lupus Pernio
Erythema Nodosum
Papular Sarcoidosis
Plaque Sarcoidosis
Subcutaneous Sarcoidosis
6.12. Global Sarcoidosis Market, Sub-Segmentation Of Renal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Granulomatous Interstitial Nephritis
Nephrocalcinosis
Hypercalciuria-Induced Kidney Disease
6.13. Global Sarcoidosis Market, Sub-Segmentation Of Hepatic Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Granulomatous Hepatitis
Portal Hypertension
Hepatic Fibrosis
6.14. Global Sarcoidosis Market, Sub-Segmentation Of Sarcoidosis Of The Spleen And Bone Marrow, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Splenomegaly
Pancytopenia
Bone Marrow Granulomas
7. Sarcoidosis Market Regional And Country Analysis
7.1. Global Sarcoidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Sarcoidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Sarcoidosis Market
8.1. Asia-Pacific Sarcoidosis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Sarcoidosis Market
9.1. China Sarcoidosis Market Overview
9.2. China Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Sarcoidosis Market
10.1. India Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Sarcoidosis Market
11.1. Japan Sarcoidosis Market Overview
11.2. Japan Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Sarcoidosis Market
12.1. Australia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Sarcoidosis Market
13.1. Indonesia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Sarcoidosis Market
14.1. South Korea Sarcoidosis Market Overview
14.2. South Korea Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Sarcoidosis Market
15.1. Western Europe Sarcoidosis Market Overview
15.2. Western Europe Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Sarcoidosis Market
16.1. UK Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Sarcoidosis Market
17.1. Germany Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Sarcoidosis Market
18.1. France Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Sarcoidosis Market
19.1. Italy Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Sarcoidosis Market
20.1. Spain Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Sarcoidosis Market
21.1. Eastern Europe Sarcoidosis Market Overview
21.2. Eastern Europe Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Sarcoidosis Market
22.1. Russia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Sarcoidosis Market
23.1. North America Sarcoidosis Market Overview
23.2. North America Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Sarcoidosis Market
24.1. USA Sarcoidosis Market Overview
24.2. USA Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Sarcoidosis Market
25.1. Canada Sarcoidosis Market Overview
25.2. Canada Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Sarcoidosis Market
26.1. South America Sarcoidosis Market Overview
26.2. South America Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Sarcoidosis Market
27.1. Brazil Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Sarcoidosis Market
28.1. Middle East Sarcoidosis Market Overview
28.2. Middle East Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Sarcoidosis Market
29.1. Africa Sarcoidosis Market Overview
29.2. Africa Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Sarcoidosis Market Competitive Landscape And Company Profiles
30.1. Sarcoidosis Market Competitive Landscape
30.2. Sarcoidosis Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Sarcoidosis Market Other Major And Innovative Companies
31.1. Bristol-Myers Squibb Company
31.2. Fresenius Kabi USA LLC
31.3. AstraZeneca plc
31.4. GlaxoSmithKline plc (GSK)
31.5. Eli Lilly and Company
31.6. Boehringer Ingelheim GmbH
31.7. Regeneron Pharmaceuticals Inc.
31.8. UCB Pharma
31.9. Sun Pharmaceutical Industries Ltd.
31.10. Cipla Ltd.
31.11. Lupin Limited
31.12. Mallinckrodt Pharmaceuticals
31.13. Xentria Inc.
31.14. Molecure SA
31.15. Relief Therapeutics Holding AG
32. Global Sarcoidosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Sarcoidosis Market
34. Recent Developments In The Sarcoidosis Market
35. Sarcoidosis Market High Potential Countries, Segments and Strategies
35.1 Sarcoidosis Market In 2029 - Countries Offering Most New Opportunities
35.2 Sarcoidosis Market In 2029 - Segments Offering Most New Opportunities
35.3 Sarcoidosis Market In 2029 - Growth Strategies
